

# Chapter 1

## Innovating and Serving the Poor with Antiretroviral Drug Systems: Advances in the HIV Brazilian Program

**Maria Matilde Zraik Baracat**  
*Federal University of Parana, Brazil*

**Farley Simon Nobre**  
*Federal University of Parana, Brazil*

### **EXECUTIVE SUMMARY**

*This chapter presents an exploratory study about the Brazilian program on Human Immunodeficiency Virus (HIV). It highlights the social and technological contributions, which have resulted from the production of antiretroviral drugs by the pharmaceutical industry in Brazil. First, this chapter reviews literature on the history of HIV epidemic and presents the HIV context as a pathology that affects the health of countries, putting at risk their economic and social development. Second, it analyzes the current situation of this epidemic in Brazil, by characterizing the Brazilian Pharmaceutical Industry (BPI). Third, this chapter elucidates the Brazilian production of antiretroviral drugs mainly based on aspects of patent law and Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). Results show that the adoption of the Brazilian program for HIV has been successful and encouraged its diffusion to, and adoption by, other countries due to its capability for wide and unrestricted distribution of medicines.*

DOI: 10.4018/978-1-4666-2842-7.ch001

## **ORGANIZATIONAL BACKGROUND**

Industrialized societies in the late twentieth century boasted of being able to control all infectious diseases through immunization or treatment (Greco, 2008). In this context, the emergence of the epidemic of Acquired Immunodeficiency Syndrome (AIDS/HIV), involving various aspects of human relations has opened a new discussion on public health, involving the allocation of financial resources for research, production and distribution of drugs such severity and lethality.

The latest figures show a 16-fold increase in the number of people receiving antiretroviral (ARV) between 2003 and 2010. According to the report UNHIV/ UNHIV for the World Day to Combat AIDS/HIV in 2011, about 34 million people worldwide are living with this disease. An additional 2.5 million deaths were avoided in low-income countries and average since 1995 due to the intensification of antiretroviral therapy. Almost half of people (47%) with indication for antiretroviral therapy are already under treatment. However, about 9 million people were eligible for therapy, have not received it in 2010. Solving this problem of access to antiretroviral treatment is the goal of the new strategy of the World Health Organization in the period 2011-2015<sup>1</sup>.

The United Nations (UN) in its annual report for 2002, recognizes the need to improve the health of the poor and marginalized as essential for economic, social and environmental development (UN, 2012). The Human Development Report (HDR) published by the United Nations Development Programme (UNDP) in 2010 highlighted the challenges the world faces related to environmental damage that endanger life on the planet, as well as the economic and social inequality that exists even in more developed countries. The World Commission on Environment and Development states in its report entitled “Our Common Future” that is not possible to separate human development of sustainable development and considers this one of the most important social movements of this new century and millennium. In this context, the need for improving health conditions for the marginalized and less fortunate populations represent a challenge for countries in general requiring efforts and partnerships in the organization of policies in this area. These efforts and partnerships, becomes essential because there is a growing awareness of the central role of health, science and technology as requirements for economic and social development and not just its consequences.

Among the factors that act as barriers to expanding access to medicines are inadequate structures of the countries for the provision of health services and insufficient funds for the purchase and production of medicines (Grangeiro, 2006). Latin America has a tradition of income concentrations in the countryside and marginalization in the slums at the outskirts of large cities therefore, any growth strategy

17 more pages are available in the full version of this document, which may be purchased using the "Add to Cart" button on the publisher's webpage: [www.igi-global.com/chapter/innovating-serving-poor-antiretroviral-drug/73288](http://www.igi-global.com/chapter/innovating-serving-poor-antiretroviral-drug/73288)

## Related Content

---

### Genetic Programming for Automatically Constructing Data Mining Algorithms

Alex A. Freitas and Gisele L. Pappa (2009). *Encyclopedia of Data Warehousing and Mining, Second Edition* (pp. 932-936).

[www.irma-international.org/chapter/genetic-programming-automatically-constructing-data/10932](http://www.irma-international.org/chapter/genetic-programming-automatically-constructing-data/10932)

### Uncertainty Operators in a Many-Valued Logic

Herman Akdag and Isis Truck (2009). *Encyclopedia of Data Warehousing and Mining, Second Edition* (pp. 1997-2003).

[www.irma-international.org/chapter/uncertainty-operators-many-valued-logic/11093](http://www.irma-international.org/chapter/uncertainty-operators-many-valued-logic/11093)

### Learning Kernels for Semi-Supervised Clustering

Bojun Yan (2009). *Encyclopedia of Data Warehousing and Mining, Second Edition* (pp. 1142-1145).

[www.irma-international.org/chapter/learning-kernels-semi-supervised-clustering/10965](http://www.irma-international.org/chapter/learning-kernels-semi-supervised-clustering/10965)

### Modeling Quantiles

Claudia Perlich, Saharon Rosset and Bianca Zadrozny (2009). *Encyclopedia of Data Warehousing and Mining, Second Edition* (pp. 1324-1329).

[www.irma-international.org/chapter/modeling-quantiles/10993](http://www.irma-international.org/chapter/modeling-quantiles/10993)

### Cluster Validation

Ricardo Vilalta and Tomasz Stepinski (2009). *Encyclopedia of Data Warehousing and Mining, Second Edition* (pp. 231-236).

[www.irma-international.org/chapter/cluster-validation/10826](http://www.irma-international.org/chapter/cluster-validation/10826)